EVALUATION OF NERIDRONATE ON THE OSSEOINTEGRATION PROCESS OF ENDEOUS TITANIUM IMPLANTS IN ANIMAL MODELS

被引:10
作者
Berardi, D.
De Benedittis, S.
Scoccia, A.
Perfetti, G.
机构
[1] Univ G dAnnunzio, Sch Med, Dept Stomatol & Oral Sci, Chieti, Italy
[2] Univ G dAnnunzio, Sch Dent, Dept Stomatol & Oral Sci, Chieti, Italy
关键词
aminobisphosphonate; neridronate; dental implants; osseointegration; bone-implant contact; BONE-RESORPTION; PAGETS-DISEASE; IN-VITRO; BISPHOSPHONATES; ALENDRONATE; SURFACE; RATS; PAMIDRONATE; CLODRONATE; DENSITY;
D O I
10.1177/1721727X1100900208
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
071005 [微生物学]; 100108 [医学免疫学];
摘要
Bisphosphonates are compounds that inhibit bone reabsorption mediated by osteoclasts. The use of bisphosphonates in oral implantology is still in the experimental stage. The aim of this study is to evaluate the efficacy of an aminobisphosphonate to increase the ability of the drug to act on the implant and bone surfaces in the development of the osseointegration in sheep. Forty SLA titanium implants were used on sheep iliac crests. Neridronate added to connective gel (test 1) or to physiological solution (test 2) was used in order to increase the bone and implant adhesiveness. Physiological solution (control 1) or connective gel (control 2) alone was given to the control groups. A topical administration of Neridronate was made on the implant surface and in the implant site. Four Bergamasca sheep were used and were sacrificed by intravenous injection of 10 cc Tanax after 8 weeks from implantation. Histologic and histomorphometric analyses were carried out. The results did not show significant differences between the test group and control group. Our data are different from other similar studies obtaining statistically significant differences. These differences could depend on the procedure of application of the drug on the implant. This study demonstrates the poor efficacy of neridronate applied topically to the implant and implant site during surgery. Further studies using different fixation techniques of the drug may be necessary to confirm the present data.
引用
收藏
页码:141 / 149
页数:9
相关论文
共 30 条
[1]
OSSEOINTEGRATED TITANIUM IMPLANTS - REQUIREMENTS FOR ENSURING A LONG-LASTING, DIRECT BONE-TO-IMPLANT ANCHORAGE IN MAN [J].
ALBREKTSSON, T ;
BRANEMARK, PI ;
HANSSON, HA ;
LINDSTROM, J .
ACTA ORTHOPAEDICA SCANDINAVICA, 1981, 52 (02) :155-170
[2]
Topical, single dose bisphosphonate treatment reduced bone resorption in a rat model for prosthetic loosening [J].
Åstrand, J ;
Aspenberg, P .
JOURNAL OF ORTHOPAEDIC RESEARCH, 2004, 22 (02) :244-249
[3]
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma [J].
Berenson, JR ;
Lichtenstein, A ;
Porter, L ;
Dimopoulos, MA ;
Bordoni, R ;
George, S ;
Lipton, A ;
Keller, A ;
Ballester, O ;
Kovacs, MJ ;
Blacklock, HA ;
Bell, R ;
Simeone, J ;
Reitsma, DJ ;
Heffernan, M ;
Seaman, J ;
Knight, RD .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (08) :488-493
[4]
The management of Paget's disease of bone [J].
Delmas, PD ;
Meunier, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (08) :558-566
[5]
Reduction in new metastases in breast cancer with adjuvant clodronate treatment [J].
Diel, IJ ;
Solomayer, EF ;
Costa, SD ;
Gollan, C ;
Goerner, R ;
Wallwiener, D ;
Kaufmann, M ;
Bastert, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (06) :357-363
[6]
DOUGLAS DL, 1980, LANCET, V1, P1043
[7]
Local and systemic conditions potentially compromising osseointegration - Consensus report of Working Group 3 [J].
Flemmig, Thomas F. .
CLINICAL ORAL IMPLANTS RESEARCH, 2006, 17 :160-162
[8]
DIPHOSPHONATES INHIBIT FORMATION OF CALCIUM PHOSPHATE CRYSTALS IN VITRO AND PATHOLOGICAL CALCIFICATION IN VIVO [J].
FRANCIS, MD ;
RUSSELL, RGG ;
FLEISCH, H .
SCIENCE, 1969, 165 (3899) :1264-&
[9]
Francis RM, 1998, CURR THER RES, V56, P831
[10]
Friberg B., 1991, INT J ORAL MAX IMPL, V6, P142